Video

Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPC

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

William K. Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, and director of the Division of Solid Tumor Oncology at Sidney Kimmel Cancer Center, discusses the next steps with the combination of radium-223 dichloride (Xofigo) and niraparib (Zejula) in metastatic castration-resistant prostate cancer (mCRPC).

Results from a phase 1b dose-finding study (NCT03076203) showed reduced prostate-specific antigen and alkaline phosphatase levels with radium-223/niraparib in chemotherapy-naïve patients with mCRPC. 

The trial evaluated an unselected patient population, explains Kelly.

A subgroup analysis of patients with DNA damage repair (DDR) alterations is being conducted to determine the efficacy of the combination in that subset of patients, says Kelly.

Additionally, an expanded phase 2 study is investigating the combination in chemotherapy-naïve patients who do not have DDR mutations, concludes Kelly.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity